You are here
Johnson & Johnson's Stelara shows promise against lupus in study
JOHNSON & Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a mid-stage clinical trial, according to data released on Saturday.
Stelara, a biotech drug known
CALL +65 6388 3838 EMAIL email@example.com